Allschwil, Switzerland – January 10, 2022 Idorsia Ltd (SIX: IDIA) today announced that the US Food and Drug Administration (FDA) has approved Quviviq (daridorexant) 25 mg and 50 mg for the treatment of adult patients with insomnia,…Original Article
FDA Approves Quviviq (daridorexant) for the Treatment of Adults with Insomnia
